Por favor, use este identificador para citar o enlazar este ítem:
https://hdl.handle.net/10495/43064
Título : | The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease |
Autor : | Baena Pineda, Ana Yulied Bocanegra García, Orfa Yamile Lopera Restrepo, Francisco Javier Vila Castelar, Clara Muñoz, Nathalia Papp, Kathryn V. Amariglio, Rebecca E. Guzmán Vélez, Edmarie Sánchez, Justin S. Reiman, Eric M. Johnson, Keith A. Sperling, Reisa A. Rentz, Dorene M. Quiroz Gaviria, Yakeel Tatiana |
metadata.dc.subject.*: | Alzheimer Disease Enfermedad de Alzheimer Cognition Cognición Positron-Emission Tomography Tomografía de Emisión de Positrones Presenilin-1 Presenilina-1 https://id.nlm.nih.gov/mesh/D053764 https://id.nlm.nih.gov/mesh/D000544 https://id.nlm.nih.gov/mesh/D003071 https://id.nlm.nih.gov/mesh/D049268 |
Fecha de publicación : | 2020 |
Editorial : | BMC (BioMed Central) |
Citación : | Vila-Castelar C, Muñoz N, Papp KV, Amariglio RE, Baena A, Guzmán-Vélez E, Bocanegra Y, Sanchez JS, Reiman EM, Johnson KA, Sperling RA, Lopera F, Rentz DM, Quiroz YT. The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimers Res Ther. 2020 Sep 10;12(1):104. doi: 10.1186/s13195-020-00671-w. |
Resumen : | ABSTRACT: Background: To determine whether performance on the Latin American Spanish version of the Face-Name Associative Memory Exam (LAS-FNAME) can differentiate between cognitively intact carriers of an autosomal dominant Alzheimer's disease mutation (E280A) in Presenilin-1, who are genetically determined to develop early-onset dementia, from matched non-carriers. We also sought to examine whether LAS-FNAME performance is associated with amyloid-β and regional tau burden in mutation carriers. Methods: A total of 35 cognitively intact mutation carriers (age range 26-41), 19 symptomatic carriers, and 48 matched non-carriers (age range 27-44) completed a neuropsychological assessment including the LAS-FNAME. A subset of participants (31 carriers [12 symptomatic] and 35 non-carriers) traveled from Colombia to Boston to undergo positron emission tomography (PET) using Pittsburgh compound B to measure mean cortical amyloid-β and flortaucipir for regional tau. ANOVA analyses and Spearman correlations were used to examine group differences and relationships among LAS-FNAME performance and amyloid-β and tau accumulation. Results: Compared to non-carriers, cognitively intact mutation carriers had lower scores on the LAS-FNAME Total Scores (p = .040). Across all carriers (including symptomatic carriers), higher levels of amyloid-β (r = - .436, p = .018) and regional tau in the entorhinal (r = - .394, p = .031) and inferior temporal cortex (r = - .563, p = .001) were associated with lower LAS-FNAME Total Scores. Conclusions: Performance on the LAS-FNAME differentiated between cognitively intact mutation carriers from non-carriers and was associated with greater amyloid and tau burden when examining all carriers. Findings suggest that the LAS-FNAME is sensitive to early clinical and pathological changes and can potentially help track disease progression in Spanish-speaking individuals. Keywords: Alzheimer’s disease; Associative memory; Autosomal dominant Alzheimer’s disease; Imaging; Neuropsychology; PET. |
metadata.dc.identifier.eissn: | 1758-9193 |
metadata.dc.identifier.doi: | 10.1186/s13195-020-00671-w |
Aparece en las colecciones: | Artículos de Revista en Ciencias Médicas |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
BaenaAna_2020_Associative_Memory_Exam.pdf | Artículo de investigación | 2.75 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons